Efficacy and Safety of Dupilumab Up to 52 Weeks in Adults and Adolescents With Eosinophilic Oesophagitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Gastroenterology & Hepatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Lancet Gastroenterol Hepatol 2023 Aug 31;[EPub Ahead of Print], ME Rothenberg, ES Dellon, MH Collins, I Hirano, M Chehade, AJ Bredenoord, AJ Lucendo, JM Spergel, X Sun, JD Hamilton, E Mortensen, E Laws, J Maloney, LP Mannent, E McCann, X Liu, L Glotfelty, A ShabbirFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.